{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:24:44Z","timestamp":1782797084568,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.clinthera.2009.03.010","type":"journal-article","created":{"date-parts":[[2009,4,23]],"date-time":"2009-04-23T08:28:42Z","timestamp":1240475322000},"page":"514-526","source":"Crossref","is-referenced-by-count":56,"title":["Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study"],"prefix":"10.1016","volume":"31","author":[{"given":"Paul","family":"Karpecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"DePaolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy A.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Rigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne S.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale W.","family":"Usner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Paterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Comstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.03.010_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0896-1549(05)70145-0","article-title":"Therapy for bacterial conjunctivitis","volume":"12","author":"Diamant","year":"1999","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.clinthera.2009.03.010_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001211.pub2","article-title":"Antibiotics versus placebo for acute bacterial conjunctivitis","volume":"2","author":"Sheikh","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2009.03.010_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0420.2007.01006.x","article-title":"Acute bacterial conjunctivitis","volume":"86","author":"H\u00f8vding","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3949\/ccjm.75.7.507","article-title":"Bacterial conjunctivitis: A review for internists","volume":"75","author":"Tarabishy","year":"2008","journal-title":"Cleve Clin J Med"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.03.010_bib5","first-page":"29S","article-title":"Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis","volume":"112","author":"Leibowitz","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib6","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/archopht.1992.01080210052022","article-title":"Ofloxacin vs tobramycin for the treatment of external ocular infection","volume":"110","author":"Gwon","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/bjo.76.12.714","article-title":"Topical ofloxacin compared with gentamicin in the treatment of external ocular infection","volume":"76","author":"Gwon","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/bjo.87.8.1004","article-title":"A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis","volume":"87","author":"Hwang","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0161-6420(02)01894-8","article-title":"A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis","volume":"110","author":"Schwab","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2009.03.010_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1091-8531(03)00168-X","article-title":"Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients","volume":"7","author":"Lichtenstein","year":"2003","journal-title":"J AAPOS"},{"key":"10.1016\/j.clinthera.2009.03.010_bib11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1185\/030079905X30699","article-title":"A randomized, investigatormasked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis","volume":"21","author":"Yee","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2009.03.010_bib12","first-page":"48","article-title":"Twice-a-day versus four-times-a-day ofloxacin treatment of external ocular infections","volume":"24","author":"Friedlaender","year":"1998","journal-title":"CLAO J"},{"key":"10.1016\/j.clinthera.2009.03.010_bib13","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0886-3350(00)00473-9","article-title":"Effect of topical ciprofloxacin 0.3% and ofloxacin 0.3% on the reduction of bacterial flora on the human conjunctiva","volume":"26","author":"Snyder-Perlmutter","year":"2000","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.clinthera.2009.03.010_bib14","article-title":"Moxifloxacin ophthalmic solution 0.5% hastens cure and eradicates the causative pathogens of bacterial conjunctivitis in pediatric and adult patients","volume":"44","author":"Katz","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.03.010_bib15","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.survophthal.2004.01.004","article-title":"Fluoroquinolone resistance in ophthalmology and the potential role for new ophthalmic fluoroquinolones","volume":"49","author":"Hwang","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.03.010_bib16","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.survophthal.2005.05.005","article-title":"Future of ophthalmic antiinfective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX)","volume":"50","author":"Schlech","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/dkn528","article-title":"Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli","volume":"63","author":"Cambau","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.03.010_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/jop.2006.0137","article-title":"Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use","volume":"23","author":"Ward","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2009.03.010_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ajo.2008.01.025","article-title":"Ocular TRUST: Nationwide antimicrobial susceptibility patterns in ocular isolates","volume":"145","author":"Asbell","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jinf.2004.03.007","article-title":"Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001\/2002","volume":"49","author":"Morrissey","year":"2004","journal-title":"J Infect"},{"key":"10.1016\/j.clinthera.2009.03.010_bib22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archopht.124.4.479","article-title":"In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates","volume":"124","author":"Miller","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib23","series-title":"Ophthalmic Drug Facts","year":"2008"},{"key":"10.1016\/j.clinthera.2009.03.010_bib24","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2009.03.010_bib25","first-page":"3","article-title":"Clinical development of 1% azithromycin in DuraSite\u00ae, a topical azalide anti-infective for ocular surface therapy","volume":"1","author":"Friedlaender","year":"2007","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib27","unstructured":"Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Sixth Edition. CLSI Document M7-A6. Wayne, Pa: CLSI; 2003."},{"key":"10.1016\/j.clinthera.2009.03.010_bib30","series-title":"Categorical Data Analysis","author":"Agresti","year":"1990"},{"key":"10.1016\/j.clinthera.2009.03.010_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000055655","article-title":"In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes","volume":"33","author":"Egger","year":"2001","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.clinthera.2009.03.010_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000084270","article-title":"Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics","volume":"37","author":"Kaliamurthy","year":"2005","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.clinthera.2009.03.010_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/112067219200200202","article-title":"The safety and efficacy of topical norfloxacin compared with placebo in the treatment of acute, bacterial conjunctivitis","volume":"2","author":"Miller","year":"1992","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib35","unstructured":"Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. In press."},{"key":"10.1016\/j.clinthera.2009.03.010_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.iio.0000212139.62428.e6","article-title":"Evidence-based review of moxifloxacin","volume":"46","author":"O'Brien","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.clinthera.2009.03.010_bib37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3928\/15428877-20071101-01","article-title":"Endophthalmitis caused by Staphylococcus epidermidis: In vitro antibiotic susceptibilities and clinical outcomes","volume":"38","author":"Miller","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.clinthera.2009.03.010_bib38","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jcrs.2007.04.015","article-title":"Fourth-generation fluoroquinolone-resistant bacterial keratitis","volume":"33","author":"Jhanji","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.clinthera.2009.03.010_bib39","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ajo.2006.06.030","article-title":"In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates","volume":"142","author":"Kotlus","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib40","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ajo.2006.05.044","article-title":"Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin","volume":"142","author":"Deramo","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.03.010_bib41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.icl.0000215432.96891.1f","article-title":"Susceptibility testing of clinical isolates of Pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating Pseudomonas ocular infections","volume":"32","author":"Epstein","year":"2006","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.clinthera.2009.03.010_bib42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/CMR.12.1.147","article-title":"Antiseptics and disinfectants: Activity, action, and resistance","volume":"12","author":"McDonnell","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2009.03.010_bib43","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1179\/joc.2007.19.2.146","article-title":"Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus","volume":"19","author":"Blondeau","year":"2007","journal-title":"J Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180900085X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180900085X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T17:44:44Z","timestamp":1589737484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929180900085X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S014929180900085X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.03.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}